Oncology Xagena
The FDA ( U.S. Food and Drug Administration ) approved Aromasin ( Exemestane tablets ) for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two- ...
Hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have ...
Hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen were 17% more likely to be alive and were 25% less likely to have ...
New data from the Intergroup Exemestane Study ( IES ) showed that hormone sensitive postmenopausal early breast cancer patients who switched to Exemestane ( Aromasin ) after 2 to 3 years of Tamoxifen ...
Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has found that anticancer drugs aren't the only culprits. Among 64 breast c ...
Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has found that anticancer drugs aren't the only culprits. Among 64 breast c ...
Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early breast cancer have each reached the same conclusion: ar ...
